Raystation 2024a SP3
Raysearch Laboratories Ab (Publ)
FDA Clearance Information
The RayStation 2024a SP3, manufactured by Raysearch Laboratories Ab (Publ), received FDA clearance via the 510k pathway on December 22, 2025. It is classified as a Class 2 device under product code MUJ.
What It Is
FDA-Cleared Indications
- The FDA-cleared indication is not provided in the supplied record.
- The product code MUJ and the available device name do not support a dialysis-access indication.
Clinical Applications
Practical Considerations
- Confirm the complete FDA 510(k) summary and labeling before describing specific clinical indications or treatment functions.
- This is software rather than an implanted or catheter-based device, so physical device size, vessel compatibility and implant duration do not apply.
- Use requires validated installation, appropriate user training and compatibility with the institution's radiation therapy equipment and information systems.
- MRI safety depends on the MRI scanner, imaging workflow and any connected hardware; the software itself should not be described as an MRI device without labeling support.
- Clinical use should follow the manufacturer's instructions, institutional quality assurance procedures and applicable radiation safety requirements.
Frequently Asked Questions
What is RayStation 2024a SP3 used for?
RayStation 2024a SP3 is used for planning and executing dialysis access procedures, ensuring precise placement and maintenance of access points.
What specialties typically use this device?
Nephrologists and vascular surgeons typically use this device in dialysis centers and hospitals.
What are the FDA-cleared indications?
The device is indicated for use in creating and maintaining dialysis access for patients with end-stage renal disease.